MPN Education Foundation


Donate Now

Join the MPN-NET Online Support

The mission of MPN-NET, and Online Forum, is to bring information, education and support to our members

Join Now

2019 MPN Heroes Recognition Program

Nominations are now open for the 2019 MPN Heroes® Recognition Program!

Nominate Now

Myeloproliferative Neoplasms

Myeloproliferative neoplasms (MPN) are relatively rare chronic hematologic malignancies that include the classic Myeloproliferative Neoplasm Disorders:

Philadelphia chromosome-negative
Essential Thrombocythemia (ET)
Myelofibrosis (MF)
Polycythemia Vera (PV)

Philadelphia chromosome-positive
Chronic Myelogenous Leukemia (CML)

There are atypical Myeloproliferative Neoplasm Disorders which include molecularly defined PDGFRA-rearranged eosinophilic/mast cell disorders; PDGFRB-rearranged eosinophilic disorders; systemic mastocytosis associated with c-kit mutation; 8p11 Myeloproliferative syndrome; and juvenile myelomonocytic leukemia with recurrent mutations of RAS. MPN also includes the clinicopathologically assigned variants: chronic neutrophilic leukemia; chronic eosinophilic leukemia; hypereosinophillic syndrome, chronic basophilic leukemia, chronic monomyelomonocytic leukemia, systemic mastocytosis; and unclassified myeloproliferative disorder. Chronic myeloid disorders also include myelodysplastic syndrome.

If you or a loved one have been diagnosed with one of these rare disorders,

Click Here to join MPN-NET Support.


Scientific Advisory Board:
John Camoriano, MD, Mayo Clinic, Scottsdale, Arizona
Joachim Deeg, MD, Fred Hutchinson Cancer Research Center, Seattle, Washington
Claire Harrison, MD, Guy’s and St. Thomas’ Hospital, London, UK
Ruben Mesa, MD, UT Health San Antonio TX
Ayalew Tefferi, MD, Mayo Clinic, Rochester, Minnesota
Srdan Verstovsek, MD, MD Anderson Cancer Center, Houston, Texas

Calling all MPN Patients!

We need your help to Guide FDA Drug Development (take 2 minutes to have an impact):

The MPN Research Foundation, in partnership with your MPN Education Foundation and MPN-NET, UT San Antonio/Drs. Mesa and Scherber, other MPN physician experts, as well as The Leukemia & Lymphoma Society (LLS) and other MPN advocates, is holding a Patient Focused Drug Development (PFDD) meeting with the US Food and Drug Administration (FDA) this September. This meeting is conducted under a new FDA program to ensure that wishes and needs of real patients are addressed by drug development.

If you are living with PV, ET or MF, we want to make sure your voice counts and is heard by the FDA.

Therefore, the partners in this important effort are collecting oral feedback for the FDA via a truly brief phone survey in which we ask only that you answer two questions:

1.    What has been the most difficult part of living with this disease for you?
2.    How has your diagnosis impacted the fulfillment of your life goals?

This phone survey will only be open for the month of July so please don’t delay dialing at your earliest convenience to let *your* voice be heard. The responses to this survey will be used in an audio montage of patient testimony during the meeting as well as in the follow-up “Voice of the Patient” report.

**The number to dial is (877) 851-5399.**

This meeting is open to the public and while in-person registration for the meeting is closed you can participate via webinar (i.e. on the computer). We will keep you informed about how to participate when details are released.  Our goal is to represent all perspectives from the MPN community so that FDA is as well informed as possible about YOUR experience living PV, ET, and MF as they look at clinical trial designs, data, outcome measures, etc.  Please help now to make your voice heard!

Detailed information about the FDA’s Patient Focused Drug Development program, and the meetings supporting it can be found here, but please call before you read it all!

Press "ESC" key to close this message.